Bangalore: MedGenome, a genomics-based diagnostic and research company distributing the best of healthcare by decoding genetic information, secures $20 million in Series B round of funding from Sequoia Capital expediting the expansion of genetic tests, enhanced sequencing facilities in India and the U.S. MedGenome is a pioneer in introducing advanced genomic technologies in the country with the latest one being the launch of Natera’s Panorama – Non-Invasive Prenatal Test (NIPT) integrating to the current offering of more than 100 genetic tests in multiple diseases which include cancer, ocular perceiver, neurological disorders, metabolic diseases and other recherché cancers.
Sam Santhosh, CEO, MedGenome, explicates, “India suffers the largest encumbrance of inherited diseases with about 5-6% of the children born affected. Further, the adoption of Western lifestyles has largely incremented the occurrence of diabetes, cancer and cardiovascular disease. Our genomic sequencing capabilities and potent interpretation provide actionable insights to clinicians sanctioning them to adopt precision medicine in their practice while our research solutions have enabled us to develop deep insights into diseases at the genetic and molecular level”.
MedGenome offers a genomic-based end-to-end diagnostics in India with a state-of-the-art Next Generation Sequencing (NGS) in Bangalore. To determine the genetic reasons underlying disease, this company uses advance genomics, immensely colossal data analytics and bioinformatics to avail in developing comprehensive gene panels for clinical diagnostics and precise analysis.
“The influx of next generation sequencing and high-throughput data is transmuting the landscape of computational biology. This has resulted in the desideratum for more robust infrastructure, implements, and techniques for genomic analysis. MedGenome has firmly established itself as an ecumenical market bellwether in genomics-based diagnostics and research from India,” verbally expressed Abhay Pandey, Managing Director of Sequoia Capital.
Earlier in Series A round of funding, MedGenome secured $4 million from Emerge Ventures. The conclusion of Series B funding will optically discern Abhay Pandey, Sequoia Capital, joining Sam Santhosh, Mahesh Pratapneni (Emerge Ventures) and Dhiraj Rajaram (Mu Sigma) in the Board of Directors.
Being the first mover in genomics-based diagnostics, it now operates the largest privately owned plenarily independent NGS lab in India. MedGenome has already grown to become the most advanced player setting the standards for other emerging candidates.